HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier.

Abstract
64 out-patients suffering from recurrent UTI were treated under double-blind conditions with one capsule daily of either the biological response modifier OM-8930 or the placebo for 3 months, followed by a 3-month observation period. Dysuria, bacteriuria, leucocyturia and antibiotic or chemotherapeutic consumption showed a significant reduction under OM-8930 in comparison with the placebo. As to the tolerance, a single case of allergic exanthema on the neck was observed in the OM-8930 group. Both the curative efficacy in the acute crisis and the consolidative efficacy in preventing further recurrences showed a highly significant superior effect of OM-8930 with respect to the placebo.
AuthorsC Frey, W Obolensky, H Wyss
JournalUrologia internationalis (Urol Int) Vol. 41 Issue 6 Pg. 444-6 ( 1986) ISSN: 0042-1138 [Print] Switzerland
PMID3547993 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adjuvants, Immunologic
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Adult
  • Aged
  • Aged, 80 and over
  • Escherichia coli (immunology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Urinary Tract Infections (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: